- List
- By Topic
- On Map
- Search Details

17363529 [PUBMED-IDS]
Need help? See RSS Feeds
Choose a feed type:

17363529 [PUBMED-IDS] (4 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT03447678 | Recruiting | Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
65 | All | 18 Years and older (Adult, Older Adult) | NCT03447678 | INT 178-17 | PEOPLE | May 23, 2018 | May 1, 2021 | May 1, 2021 | February 27, 2018 | June 5, 2018 |
|
||
2 | NCT03330834 | Not yet recruiting | CAR-T Cell Immunotherapy for Advanced Lung Cancer |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
22 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT03330834 | CART-YY2017 | November 20, 2017 | March 31, 2019 | September 30, 2019 | November 6, 2017 | November 7, 2017 | ||||
3 | NCT02906332 | Active, not recruiting | Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
16 | All | 18 Years to 99 Years (Adult, Older Adult) | NCT02906332 | Pro2016-0262 | December 12, 2016 | December 2018 | July 2019 | September 20, 2016 | October 2, 2018 |
|
|||
4 | NCT02591615 | Recruiting | Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
90 | All | 18 Years and older (Adult, Older Adult) | NCT02591615 | AFT-09 | March 2016 | April 2019 | December 2019 | October 29, 2015 | April 13, 2018 |
|
† Study has passed its completion date and status has not been verified in more than two years.